This year, ASCO’s theme was “Collaborating to Conquer Cancer.” There is no better place than the “Windy City”, to accommodate the 34,000 people that attended this meeting.
As a current metastatic breast cancer patient & advocate, I was particularly impressed to hear about the T-DM1 (EMILIA) phase 111 results for advanced Her2-positive Breast Cancer . The results showed that T-DM1 demonstrated greater efficacy & safety than capecitababine/lapatinib. T-DM1 should offer an important therapeutic option for the treatment of Her2-positive advanced Breast Cancer. Read more about the EMILIA study here:http://bit.ly/NrckG2
For advanced Ovarian Cancer , the results of two-phase 111 trials presented that Bevacizumab combined with chemotherapy should be considered as a standard option in platinum-resistant ovarian cancer. Read more about the AURELIA phase 111 trial here:http://bit.ly/Lg3v0j
Lung Cancer treatment is an ongoing process in understanding that it is not a one-size-fits-all disease. The roles of the pathologist and surgeon seem to be critical for a multi-disciplinary approach.
“We hope that this is just the beginning of a process of change that will likely continue for several years,” Dr. Jänne said. “There are many other genetic alterations that have been found in patients with lung cancer, and active efforts are being made to look for treatments for those subsets of individuals.”
Read more about the New Era of Lung Cancer Care here: http://bit.ly/La3Cco
Clearly, there is much more information on the many types and research surrounding cancer. As a patient-advocate myself, I was honored to have the opportunity to attend this conference and gain the knowledge I needed to be an empowered patient. You can find more information about the Top Headlines of the ASCO 2012 news here: http://bit.ly/L0PSCS
“Together, we can Collaborate to Conquer Cancer.”